Jian-Xing He to Treatment Outcome
This is a "connection" page, showing publications Jian-Xing He has written about Treatment Outcome.
Connection Strength
0.325
-
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open. 2018 09 10; 8(9):e017240.
Score: 0.112
-
Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Cancer: A Meta-analysis. Ann Surg. 2018 08; 268(2):254-259.
Score: 0.028
-
Diaphragm electromyography guidance for a lung transplant recipient with difficult weaning from mechanical ventilation: A case report. Medicine (Baltimore). 2018 Jun; 97(23):e10989.
Score: 0.028
-
Thoracoscopic surgery for tracheal and carinal resection and reconstruction under spontaneous ventilation. J Thorac Cardiovasc Surg. 2018 06; 155(6):2746-2754.
Score: 0.027
-
Outcome and Safety of Radical Resection in Non-Small Cell Lung Cancer Patients via Glasses-Free 3-Dimensional Video-Assisted Thoracoscope Versus 2-Dimensional Video-Assisted Thoracoscope. Surg Innov. 2018 Apr; 25(2):121-127.
Score: 0.027
-
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Cancer Chemother Pharmacol. 2017 Jun; 79(6):1109-1117.
Score: 0.026
-
[Propensity Score Matching Analysis of VATS Lobectomy and Sublobar Resection for Stage I Lung Adenocarcinoma]. Zhongguo Fei Ai Za Zhi. 2017 Jan 20; 20(1):47-54.
Score: 0.025
-
SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. Oncotarget. 2016 Jun 28; 7(26):39970-39979.
Score: 0.024
-
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 05; 7(5):437-446.
Score: 0.007
-
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1569-1575.
Score: 0.007
-
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2018 08; 122:32-37.
Score: 0.007
-
Spontaneous ventilation thoracoscopic thymectomy without muscle relaxant for myasthenia gravis: Comparison with "standard" thoracoscopic thymectomy. J Thorac Cardiovasc Surg. 2018 04; 155(4):1882-1889.e3.
Score: 0.007